SLC5A2 and type 2 diabetes mellitus: Previous clinical trials have shown that SGLT2 inhibitors significantly reduced major cardiovascular (CV) adverse events and/or hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) at high risk of cardiovascular disease (CVD) [3–5].